A citation-based method for searching scientific literature

Omoniyi J Adedokun, Zhenhua Xu, Christopher Gasink, Douglas Jacobstein, Philippe Szapary, Jewel Johanns, Long-Long Gao, Hugh M Davis, Stephen B Hanauer, Brian G Feagan, Subrata Ghosh, William J Sandborn. Gastroenterology 2018
Times Cited: 114







List of co-cited articles
782 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Brian G Feagan, William J Sandborn, Christopher Gasink, Douglas Jacobstein, Yinghua Lang, Joshua R Friedman, Marion A Blank, Jewel Johanns, Long-Long Gao, Ye Miao,[...]. N Engl J Med 2016
821
65

Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
Robert Battat, Uri Kopylov, Talat Bessissow, Alain Bitton, Albert Cohen, Anjali Jain, Myriam Martel, Ernest Seidman, Waqqas Afif. Clin Gastroenterol Hepatol 2017
132
56

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
William J Sandborn, Christopher Gasink, Long-Long Gao, Marion A Blank, Jewel Johanns, Cynthia Guzzo, Bruce E Sands, Stephen B Hanauer, Stephan Targan, Paul Rutgeerts,[...]. N Engl J Med 2012
731
34

Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
Bram Verstockt, Erwin Dreesen, Maja Noman, An Outtier, Nathalie Van den Berghe, Isolde Aerden, Griet Compernolle, Gert Van Assche, Ann Gils, Séverine Vermeire,[...]. J Crohns Colitis 2019
51
58

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
Niels Vande Casteele, Marc Ferrante, Gert Van Assche, Vera Ballet, Griet Compernolle, Kristel Van Steen, Steven Simoens, Paul Rutgeerts, Ann Gils, Séverine Vermeire. Gastroenterology 2015
566
28

American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.
Joseph D Feuerstein, Geoffrey C Nguyen, Sonia S Kupfer, Yngve Falck-Ytter, Siddharth Singh. Gastroenterology 2017
295
26

Infliximab, azathioprine, or combination therapy for Crohn's disease.
Jean Frédéric Colombel, William J Sandborn, Walter Reinisch, Gerassimos J Mantzaris, Asher Kornbluth, Daniel Rachmilewitz, Simon Lichtiger, Geert D'Haens, Robert H Diamond, Delma L Broussard,[...]. N Engl J Med 2010
22

Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
N Mitrev, N Vande Casteele, C H Seow, J M Andrews, S J Connor, G T Moore, M Barclay, J Begun, R Bryant, W Chan,[...]. Aliment Pharmacol Ther 2017
159
22

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Bruce E Sands, William J Sandborn, Remo Panaccione, Christopher D O'Brien, Hongyan Zhang, Jewel Johanns, Omoniyi J Adedokun, Katherine Li, Laurent Peyrin-Biroulet, Gert Van Assche,[...]. N Engl J Med 2019
342
22

Vedolizumab as induction and maintenance therapy for Crohn's disease.
William J Sandborn, Brian G Feagan, Paul Rutgeerts, Stephen Hanauer, Jean-Frédéric Colombel, Bruce E Sands, Milan Lukas, Richard N Fedorak, Scott Lee, Brian Bressler,[...]. N Engl J Med 2013
21

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Nicholas A Kennedy, Graham A Heap, Harry D Green, Benjamin Hamilton, Claire Bewshea, Gareth J Walker, Amanda Thomas, Rachel Nice, Mandy H Perry, Sonia Bouri,[...]. Lancet Gastroenterol Hepatol 2019
235
21

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
L Peyrin-Biroulet, W Sandborn, B E Sands, W Reinisch, W Bemelman, R V Bryant, G D'Haens, I Dotan, M Dubinsky, B Feagan,[...]. Am J Gastroenterol 2015
20

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
Geert D'Haens, Severine Vermeire, Guy Lambrecht, Filip Baert, Peter Bossuyt, Benjamin Pariente, Anthony Buisson, Yoram Bouhnik, Jérôme Filippi, Janneke Vander Woude,[...]. Gastroenterology 2018
159
20

Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G Feagan, Paul Rutgeerts, Bruce E Sands, Stephen Hanauer, Jean-Frédéric Colombel, William J Sandborn, Gert Van Assche, Jeffrey Axler, Hyo-Jong Kim, Silvio Danese,[...]. N Engl J Med 2013
19

Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases.
Erwin Dreesen, Bram Verstockt, Sumin Bian, Magali de Bruyn, Griet Compernolle, Sophie Tops, Maja Noman, Gert Van Assche, Marc Ferrante, Ann Gils,[...]. Clin Gastroenterol Hepatol 2018
81
23

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Konstantinos Papamichael, Adam S Cheifetz, Gil Y Melmed, Peter M Irving, Niels Vande Casteele, Patricia L Kozuch, Laura E Raffals, Leonard Baidoo, Brian Bressler, Shane M Devlin,[...]. Clin Gastroenterol Hepatol 2019
121
19

Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's Disease.
Ninon Soufflet, Gilles Boschetti, Xavier Roblin, Charlotte Cuercq, Nicolas Williet, Anne-Laure Charlois, Remi Duclaux-Loras, Pauline Danion, Anne Mialon, Mathias Faure,[...]. Clin Gastroenterol Hepatol 2019
20
95

Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Paul Rutgeerts, Christopher Gasink, Daphne Chan, Yinghua Lang, Paul Pollack, Jean-Frederic Colombel, Douglas C Wolf, Douglas Jacobstein, Jewel Johanns, Philippe Szapary,[...]. Gastroenterology 2018
80
22

Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.
C Ma, R N Fedorak, G G Kaplan, L A Dieleman, S M Devlin, N Stern, K I Kroeker, C H Seow, Y Leung, K L Novak,[...]. Aliment Pharmacol Ther 2017
96
17

Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
Omoniyi J Adedokun, William J Sandborn, Brian G Feagan, Paul Rutgeerts, Zhenhua Xu, Colleen W Marano, Jewel Johanns, Honghui Zhou, Hugh M Davis, Freddy Cornillie,[...]. Gastroenterology 2014
234
17

Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.
Konstantinos Papamichael, Karen A Chachu, Ravy K Vajravelu, Byron P Vaughn, Josephine Ni, Mark T Osterman, Adam S Cheifetz. Clin Gastroenterol Hepatol 2017
135
16

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
William J Sandborn, Brian G Feagan, Richard N Fedorak, Ellen Scherl, Mark R Fleisher, Seymour Katz, Jewel Johanns, Marion Blank, Paul Rutgeerts. Gastroenterology 2008
553
16

Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.
Pauline Wils, Yoram Bouhnik, Pierre Michetti, Bernard Flourie, Hedia Brixi, Anne Bourrier, Matthieu Allez, Bernard Duclos, Jean-Charles Grimaud, Anthony Buisson,[...]. Clin Gastroenterol Hepatol 2016
123
16

Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.
Amit Assa, Manar Matar, Dan Turner, Efrat Broide, Batia Weiss, Oren Ledder, Anat Guz-Mark, Firas Rinawi, Shlomi Cohen, Chani Topf-Olivestone,[...]. Gastroenterology 2019
97
16

Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.
Henit Yanai, Lev Lichtenstein, Amit Assa, Yoav Mazor, Batia Weiss, Arie Levine, Yulia Ron, Uri Kopylov, Yoram Bujanover, Yoram Rosenbach,[...]. Clin Gastroenterol Hepatol 2015
215
15

Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort.
Sam Khorrami, Daniel Ginard, Ignacio Marín-Jiménez, María Chaparro, Mónica Sierra, Mariam Aguas, Beatriz Sicilia, Valle García-Sánchez, Cristina Suarez, Albert Villoria,[...]. Inflamm Bowel Dis 2016
105
15

Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease.
A J Yarur, V Kanagala, D J Stein, F Czul, M A Quintero, D Agrawal, A Patel, K Best, C Fox, K Idstein,[...]. Aliment Pharmacol Ther 2017
159
15

Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
Casper Steenholdt, Jørn Brynskov, Ole Østergaard Thomsen, Lars Kristian Munck, Jan Fallingborg, Lisbet Ambrosius Christensen, Gitte Pedersen, Jens Kjeldsen, Bent Ascanius Jacobsen, Anne Sophie Oxholm,[...]. Gut 2014
331
15

Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation.
Mark T Osterman, Maria Rosario, Karen Lasch, Morris Barocas, Jayson D Wilbur, Nathanael L Dirks, Marc R Gastonguay. Aliment Pharmacol Ther 2019
40
37

Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
Konstantinos Papamichael, Anna Juncadella, Danny Wong, Shana Rakowsky, Lindsey A Sattler, James P Campbell, Byron P Vaughn, Adam S Cheifetz. J Crohns Colitis 2019
68
22

Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Maria Rosario, Jonathan L French, Nathanael L Dirks, Serap Sankoh, Asit Parikh, Huyuan Yang, Silvio Danese, Jean-Frédéric Colombel, Michael Smyth, William J Sandborn,[...]. J Crohns Colitis 2017
98
15

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial.
Freddy Cornillie, Stephen B Hanauer, Robert H Diamond, Jianping Wang, Kezhen L Tang, Zhenhua Xu, Paul Rutgeerts, Séverine Vermeire. Gut 2014
267
14

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
Stephen B Hanauer, Brian G Feagan, Gary R Lichtenstein, Lloyd F Mayer, S Schreiber, Jean Frederic Colombel, Daniel Rachmilewitz, Douglas C Wolf, Allan Olson, Weihang Bao,[...]. Lancet 2002
14

Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease--the McGill experience.
U Kopylov, W Afif, A Cohen, A Bitton, G Wild, T Bessissow, J Wyse, T Al-Taweel, A Szilagyi, E Seidman. J Crohns Colitis 2014
104
14

Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.
N Vande Casteele, B G Feagan, S Vermeire, M Yassine, J Coarse, G Kosutic, W J Sandborn. Aliment Pharmacol Ther 2018
28
50

Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
Omoniyi J Adedokun, Zhenhua Xu, Colleen W Marano, Richard Strauss, Hongyan Zhang, Jewel Johanns, Honghui Zhou, Hugh M Davis, Walter Reinisch, Brian G Feagan,[...]. J Crohns Colitis 2017
76
18

Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.
W Yacoub, N Williet, L Pouillon, T Di-Bernado, M De Carvalho Bittencourt, S Nancey, A Lopez, S Paul, C Zallot, X Roblin,[...]. Aliment Pharmacol Ther 2018
68
20

Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis.
Niels Vande Casteele, Jenny Jeyarajah, Vipul Jairath, Brian G Feagan, William J Sandborn. Clin Gastroenterol Hepatol 2019
33
39

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
Bella Ungar, Idan Levy, Yarden Yavne, Miri Yavzori, Orit Picard, Ella Fudim, Ronen Loebstein, Yehuda Chowers, Rami Eliakim, Uri Kopylov,[...]. Clin Gastroenterol Hepatol 2016
237
13


Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis.
Johannan F Brandse, Ron A Mathôt, Desiree van der Kleij, Theo Rispens, Yaël Ashruf, Jeroen M Jansen, Svend Rietdijk, Mark Löwenberg, Cyriel Y Ponsioen, Sharat Singh,[...]. Clin Gastroenterol Hepatol 2016
126
13

Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing.
Bram Verstockt, Gitte Moors, Sumin Bian, Thomas Van Stappen, Gert Van Assche, Séverine Vermeire, Ann Gils, Marc Ferrante. Aliment Pharmacol Ther 2018
41
31

Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.
Christopher Ma, Richard N Fedorak, Gilaad G Kaplan, Levinus A Dieleman, Shane M Devlin, Nathan Stern, Karen I Kroeker, Cynthia H Seow, Yvette Leung, Kerri L Novak,[...]. Inflamm Bowel Dis 2017
57
22

Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study.
Vince B C Biemans, Andrea E van der Meulen-de Jong, Christine J van der Woude, Mark Löwenberg, Gerard Dijkstra, Bas Oldenburg, Nanne K H de Boer, Sander van der Marel, Alexander G L Bodelier, Jeroen M Jansen,[...]. J Crohns Colitis 2020
66
19

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.
Joana Torres, Stefanos Bonovas, Glen Doherty, Torsten Kucharzik, Javier P Gisbert, Tim Raine, Michel Adamina, Alessandro Armuzzi, Oliver Bachmann, Palle Bager,[...]. J Crohns Colitis 2020
297
13

How, When, and for Whom Should We Perform Therapeutic Drug Monitoring?
Severine Vermeire, Erwin Dreesen, Konstantinos Papamichael, Marla C Dubinsky. Clin Gastroenterol Hepatol 2020
38
34

Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis.
Omoniyi J Adedokun, Zhenhua Xu, Colleen Marano, Chris O'Brien, Philippe Szapary, Hongyan Zhang, Jewel Johanns, Rupert W Leong, Tadakazu Hisamatsu, Gert Van Assche,[...]. Clin Gastroenterol Hepatol 2020
29
44

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Jean-Frédéric Colombel, William J Sandborn, Paul Rutgeerts, Robert Enns, Stephen B Hanauer, Remo Panaccione, Stefan Schreiber, Dan Byczkowski, Ju Li, Jeffrey D Kent,[...]. Gastroenterology 2007
12

Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis.
Johannan F Brandse, Gijs R van den Brink, Manon E Wildenberg, Desiree van der Kleij, Theo Rispens, Jeroen M Jansen, Ron A Mathôt, Cyriel Y Ponsioen, Mark Löwenberg, Geert R A M D'Haens. Gastroenterology 2015
255
12

Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC Study.
Bella Ungar, Tal Engel, Doron Yablecovitch, Adi Lahat, Alon Lang, Benjamin Avidan, Ofir Har-Noy, Dan Carter, Nina Levhar, Limor Selinger,[...]. Am J Gastroenterol 2018
42
28


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.